Juvenile Rheumatoid Arthritis

Amgen

Status and phase: Completed; Phase 2

Conditions: Juvenile Chronic Arthritis

Treatments: Drug: Placebo; Drug: Anakinra

Study type: Interventional

Funder types: Industry

Identifiers

NCT00037648

990758-990779

Details and patient eligibility

About

The purpose of this study is to determine the safety of anakinra in patients with Polyarticular-Course Juvenile Rheumatoid Arthritis, a form of rheumatoid arthritis affecting children.

Enrollment: 86 patients

Sex: All

Ages: 2 to 17 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• Male or female age 2-17 yrs inclusive * Minimum weight 10 KG * Diagnosis of Chronic Arthritis

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

86 participants in 2 patient groups, including a placebo group

placebo

Placebo Comparator group

Treatment:

Drug: Placebo

anakinra

Experimental group

Treatment:

Drug: Anakinra